Analysis on Medicine Regularity of Chinese Patent Medicine in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 Based on Data Mining

Abstract

Abstract: Objective：To systematically analyze Chinese medicine prescription protocols for the prevention and treatment of COVID-19and provide references for rational drug use of Chinese patent medicine. Methods：We collected the latest prevention and treatment protocols for COVID-19 by the National Health Commission and the Chinese Medicine Administration (CMA) of each province， autonomous region and municipality directly under the Central Governments before January 10， 2023. The Ancient and Modern Medical Records Cloud Platform was used to analyze the Chinese patent medicine， and TCM syndrome. Results： Thirty-one prevention and treatment protocols were reviewed， including 2 national scheme and 28 regional ones. Therewere306 kinds of Chinese patent medicine wererecommended for adults and 109 kinds for children. Lianhua Qingwen capsules(granules) were the highest recommended frequency among early and middle stage.Tanreqing Injection and Xuebijing injection have the highest recommended frequency among severe and critical stage. Jinhua Qing granules，Lianhua Qingwen capsule (granules) and Huashibaidu granules were recommended drugs in the three clinical manifestations of fever， cough and sore throat in adults. Conclusion：Chinese patent medicine plays an important role in the prevention and treatment of COVID-19.Patients should identify different TCM syndromes according to clinical symptoms， and reasonably choose the Chinese patent medicine with different efficacy.

Key words: font-size:medium, ">COVID-19；Data mining；Chinese patent medicine；Medication patterns

CLC Number:

HAO Jia-xin, SUN Xin, WU Xiao-dan, MENG Yan-yan, FEI Yu-tong, RONG Hong-guo, . Analysis on Medicine Regularity of Chinese Patent Medicine in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 Based on Data Mining[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 101-106.

References

[1]韩煜，吴强，戎柯纬，等. 新冠肺炎的预防与新冠病毒消毒方法研究进展[J]. 中国消毒学杂志， 2021， 38(12)： 939-945.
     [2]中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案（试行第十版） [J]. 中国合理用药探索， 2023， 20(1)： 1-11.
     [3]史雨宸，高源，蔡松，等. 应用经方治疗新型冠状病毒奥密克戎感染之思考[J]. 北京中医药： 1-4.
     [4]陈莉莉，葛广波，荣艳，等. 中药在新冠肺炎防治中的应用和研究进展[J]. 上海中医药大学学报， 2020， 34(3)： 1-8.
     [5]段璨，夏文广，郑婵娟，等. 金花清感颗粒联合西医常规治疗方案治疗轻型新型冠状病毒肺炎的临床观察[J]. 中医杂志， 2020， 61(17)： 1473-1477.
     [6]田晓玲，华川，张艳，等. 连花清瘟胶囊防治新型冠状病毒肺炎研究进展[J]. 辽宁中医药大学学报， 2020， 22(8)： 184-187.
     [7]康乐，苗晋鑫，苗明三，等. 血必净类制剂治疗新冠病毒肺炎的作用特点[J]. 中药药理与临床， 2020， 36(2)： 11-15.
     [8]胡刚明，贺朝雄，孙秋凌，等. “清肺排毒颗粒”治疗新型冠状病毒肺炎的临床疗效初探[J]. 天津中医药， 2020， 37(9)： 999-1004.
     [9]于明坤，柴倩云，梁昌昊，等. 新型冠状病毒肺炎中医预防及诊疗方案汇总分析[J]. 中医杂志， 2020， 61(5)： 383-387.
     [10]陈瑞，罗亚萍，徐勋华，等. 武汉地区52例新型冠状病毒肺炎中医证治初探及典型病案分析[J]. 中医杂志， 2020， 61(9)： 741-744.
     [11]宋如珺，黄玉宇，沈夕坤，等. 新型冠状病毒肺炎诊疗方案推荐中成药的合理使用探讨[J]. 中国现代应用药学， 2020， 37(7)： 782-787.
     [12]刘洁，罗万军，邓志宏，等. 91例儿童新型冠状病毒肺炎确诊病例临床及流行病学特征[J]. 中华医院感染学杂志， 2020， 30(11)： 1625-1629.
     [13]孙军娣，张自强，何淑旺，等. 儿童口服给药固体新剂型研究进展[J]. 中国药科大学学报， 2019， 50(6)： 631-640.

[1]	DAI Qi, LI Kang-xi, YE Qiao-bo, WEN Yong-sheng, XU Li, LI Ji. Reaserch Progress on Chemical Constituents，Pharmacological Effects and Toxicology of Bombyx Batryticatus [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 402-408.
[2]	ZHAO Lei, YANG Ming, WANG Hao, MA yu, MA Jin-gan, JIANG Da-cheng, WANG Lu-hong, ZAN Ke. Investigation and Risk Assessment of Mycotoxins in Seabuckthorn during Different Harvesting Periods and Drying Processes [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 377-383.
[3]	HONG Shu-hua, LIN Qi-shan, CHAI Jiang-hong, PAN Hong-ju. Study on the Determination of Zopiclone Related Substances and the Influence of Correction Factor [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 384-388.
[4]	LI Yue-chen, CUI Shao-jing, ZHAO Yue-ran. Determination of Aflatoxins in Huoxuezhitong Capsules by High Performance Liquid Chromatography Coupled with Post-column Photochemical Derivatization [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 390-395.
[5]	TIAN Jie, HAO Ai-yu, LU Lin, ZOU Pian, DONG Bin. Effect of Several Drug Compatibility on Sub-visible Particles in Infusions with Common Plastic Packagings [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 396-401.
[6]	YANG Yan-qing, CHEN Chun-mei, CHEN Wei, Wu Rui, WANG Xue-chang, DUAN Lian. Rapid Health Technology Evaluation of Sintilimab as First-line Treatment for Advanced Non-small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 409-415.
[7]	JIANG Yi-Fan, CHEN Li-ping, ZHANG Ruo-yu, WU Pei-hao, QIU Jia-min, XUAN Jian-wei, BI Hui-chang. Construction of Clinical Comprehensive Value Evaluation System for Acid-inhibiting Drugs [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 416-421.
[8]	HUA Min-fan, SONG Cang-sang, LI Xing-de, LU Wei, MAO Pan-pan, WANG Guo-hui. Medication Adherence Forecast Model Research Progress in Clinical Application [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 422-425.
[9]	HUANG Bo, CAO Xiao-ming. Safety Analysis of Isotonic and Hypotonic Contrast Media for Coronary Angiography in Elderly Patients with Renal Impairment [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 426-429.
[10]	ZHANG Wen, YANG Wei-bing. Effects of Vitamin D Combined with Etocoxib on Rehabilitation，Bone Metabolism and Inflammation in Elderly Patients after Knee Replacement [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 430-434.
[11]	TIAN Jin-ya, DUAN Xiao-kai, FAN Shi-zhen. Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function， Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 435-438.
[12]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Introduction of Bioanalytical Strategies and Methodologies for Genetically Modified Cell Therapy Products [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 369-376.
[13]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Bioanalysis of Gene Therapy Products： Method Development Strategy [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 361-368.
[14]	ZHANG Yu, LI Yu-man, XIA Xu-dong. Analysis of Suspected ADR Monitoring Data of Ginkgo Injection Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 439-444.
[15]	YAO Qing, LIU Ying, WANG Xiao-fang, GAO Ning, WANG Miao. Excel Calculates the Population Bioequivalence of Special Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(4): 332-337.

Analysis on Medicine Regularity of Chinese Patent Medicine in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 Based on Data Mining

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments